Signaling domains of cancer-associated glycolipids.
Cancer. Tumor antigen. Carbohydrate. Glycolipid. Antibody. Raft
Journal
Glycoconjugate journal
ISSN: 1573-4986
Titre abrégé: Glycoconj J
Pays: United States
ID NLM: 8603310
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
18
12
2021
accepted:
15
02
2022
revised:
06
02
2022
pubmed:
23
3
2022
medline:
12
4
2022
entrez:
22
3
2022
Statut:
ppublish
Résumé
Immunotherapy of malignant cancers is now becoming one of representative approaches to overcome cancers. To construct strategies for immunotherapy, presence of tumor-specific antigens should be a major promise. A number of cancer specific- or cancer-associated antigens have been reported based on various experimental sets and various animal systems. The most reasonable strategy to define tumor-specific antigens might be "autologous typing" performed by Old's group, proposing three classes of tumor-antigens recognized by host immune systems of cancer patients. Namely, class 1, individual antigens that is present only in the patient's sample analyzed; class 2, shared antigens that can be found only in some group of cancers in some patients, but not in normal cells and tissues; class 3, universal antigens that are present in some cancers but also in normal cells and tissues with different densities. Sen Hakomori reported there were novel carbohydrates in cancers that could not be detected in normal cells mainly by biochemical approaches. Consequently, many of class 2 cancer-specific antigens have been revealed to be carbohydrate antigens, and been used for cancer diagnosis and treatment. Not only as cancer markers, but roles of those cancer-associated carbohydrates have also been recognized as functional molecules in cancer cells. In particular, roles of complex carbohydrates in the regulation of cell signaling on the cell surface microdomains, glycolipid-enriched microdomain (GEM)/rafts have been reported by Hakomori and many other researchers including us. The processes and present status of these studies on cancer-associated glycolipids were summarized.
Identifiants
pubmed: 35315508
doi: 10.1007/s10719-022-10051-1
pii: 10.1007/s10719-022-10051-1
doi:
Substances chimiques
Antigens, Tumor-Associated, Carbohydrate
0
Biomarkers, Tumor
0
Glycolipids
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
145-155Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Old, L.J., Boyse, E.A.: Antigenic properties of experimental leukemias. i. serological studies in vitro with spontaneous and radiation-induced leukemias. J. Natl. Cancer Inst. 31, 977–995 (1963)
pubmed: 14069836
Old, L.J., Boyse, E.A., Stockert, E.: The G (Gross) leukemia antigen. Cancer Res. 25, 813–819 (1965)
pubmed: 4284252
Old, L.J., Stockert, E.: Immunogenetics of cell surface antigens of mouse leukemia. Annu. Rev. Genet. 11, 127–160 (1977). https://doi.org/10.1146/annurev.ge.11.120177.001015
doi: 10.1146/annurev.ge.11.120177.001015
pubmed: 202188
Klein, G.: Tumor-specific transplantation antigens: G. H. A. Clowes memorial lecture. Cancer Res. 28, 625–635 (1968)
pubmed: 4870094
Klein, G., Sjogren, H.O., Klein, E., Hellstrom, K.E.: Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561–1572 (1960)
pubmed: 13756652
Morton, D.L., Miller, G.F., Wood, D.A.: Demonstration of tumor-specific immunity against antigens unrelated to the mammary tumor virus in spontaneous mammary adenocarcinomas. J. Natl. Cancer Inst. 42, 289–301 (1969)
pubmed: 4303881
Old, L.J.: Cancer Immunology: the search for specificity – G.H.A. Clows Memorial Lecture. Cancer Res. 41, 361–375 (1981)
pubmed: 7004632
Watanabe, T., Pukel, C.S., Takeyama, H., Lloyd, K.O., Shiku, H., Li, L.T., Travassos, L.R., Oettgen, H.F., Old, L.J.: Human melanoma antigen AH is an autoantigenic ganglioside related to GD2. J. Exp. Med. 156, 1884–1889 (1982). https://doi.org/10.1084/jem.156.6.1884
doi: 10.1084/jem.156.6.1884
pubmed: 7175442
Dippold, W.G., Lloyd, K.O., Li, L.T., Ikeda, H., Oettgen, H.F., Old, L.J.: Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 77, 6114–6118: (1980). https://doi.org/10.1073/pnas.77.10.6114
Pukel, C.S., Lloyd, K.O., Travassos, L.R., Dippold, W.G., Oettgen, H.F., Old, L.J.: GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J. Exp. Med. 155, 1133–1147 (1982). https://doi.org/10.1084/jem.155.4.1133
doi: 10.1084/jem.155.4.1133
pubmed: 7061953
Yamaguchi, H., Furukawa, K., Fortunato, S.R., Livingston, P.O., Lloyd, K.O., Oettgen, H.F., Old, L.J.: Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 84, 2416–2420: (1987). https://doi.org/10.1073/pnas.84.8.2416
Schrump, D.S., Furukawa, K., Yamaguchi, H., Lloyd, K.O., Old, L.J.: Recognition of galactosylgloboside by monoclonal antibodies derived from patients with primary lung cancer. Proc. Natl. Acad. Sci. USA. 85, 4441–4445: (1988). https://doi.org/10.1073/pnas.85.12.4441
Houghton, A.N., Mintzer, D., Cordon-Cardo, C., Welt, S., Fliegel, B., Vadhan, S., Carswell, E., Melamed, M.R., Oettgen, H.F., Old, L.J.: Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. U.S.A. 82, 1242–1246: (1985). https://doi.org/10.1073/pnas.82.4.1242
Irie, R.F., Morton, D.L.: Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc. Natl. Acad. Sci. U.S.A. 83, 8694–8698: (1986). https://doi.org/10.1073/pnas.83.22.8694
Cahan, L.D., Irie, R.F., Singh, R., Cassidenti, A., Paulson, J.C.: Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc. Natl. Acad. Sci. U.S.A. 79, 7629–7633: (1982). https://doi.org/10.1073/pnas.79.24.7629/
Gahmberg, C.G., Hakomori, S.: Surface carbohydrates of hamster fibroblasts. I. Chemical characterization of surface-labeled glycosphingolipids and aspecific ceramide tetrasaccharide for transformants. J. Biol. Chem. 250, 2438–2446 (1975)
doi: 10.1016/S0021-9258(19)41619-0
Hakomori, S.: Tmor-associated glycolipid antigens, their metabolism and organization. Chem. Phys. Lipids. 42, 209–233 (1986). https://doi.org/10.1016/0009-3084(86)90054-x
doi: 10.1016/0009-3084(86)90054-x
pubmed: 2435423
Lloyd, K.O.: Humoral immune responses to tumor-associated carbohydrate antigens. Semin. Cancer Biol. 2, 421–431 (1991)
pubmed: 1725731
Lloyd, K.O., Old, L.J.: Human monoclonal antibodies. Cancer Res. 49, 3445–3451 (1989)
pubmed: 2471585
Indellicato, R., Zulueta, A., Caretti, A., Trinchera, M.: Complementary Use of Carbohydrate Antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19.9 Epitope) in Gastrointestinal Cancers: Biological Rationale towards a Personalized Clinical Application. Cancers. 12, 1509 (2020). https://doi.org/10.3390/cancers12061509
doi: 10.3390/cancers12061509
pmcid: 7352550
Furukawa, K., Lloyd, K.O.: Gangliosides in melanoma. In: Ferrone, S. (ed.) Human melanoma: from basic research to clinical application. pp. 15–30. Springer, Heidelburg (1990)
Portoukalian, J., Zwingelstein, G., Doré, J.F.: Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur. J. Biochem. 94, 19–23 (1979). https://doi.org/10.1111/j.1432-1033.1979.tb12866.x
doi: 10.1111/j.1432-1033.1979.tb12866.x
pubmed: 436839
Carubia, J.M., Yu, R.K., Macala, L.J., Kirkwood, J.M., Varga, J.M.: Gangliosides of normal and neoplastic human melanocytes. Biochem. Biophys. Res. Commun. 120, 500–504 (1984). https://doi.org/10.1016/0006-291x(84)91282-8
doi: 10.1016/0006-291x(84)91282-8
pubmed: 6732768
Saito, M., Yu, R.K., Cheung, N.K.: Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem. Biophys. Res. Commun. 127, 1–7 (1985). https://doi.org/10.1016/s0006-291x(85)80117-0
Schultz, G., Cheresh, D.A., Varki, N.M., Yu, A., Staffileno, L.K., Reisfeld, R.A.: Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 44, 5914–5920 (1984)
Fredman, P., von Holst, H., Collins, V.P., Ammar, A., Dellheden, B., Wahren, B., Granholm, L., Svennerholm, L.: Potential ganglioside antigens associated with human gliomas. Neurol. Res. 8, 123–126 (1986). https://doi.org/10.1080/01616412.1986.11739744
doi: 10.1080/01616412.1986.11739744
pubmed: 2875407
Wikstrand, C.J., Fredman, P., Svennerholm, L., Bigner, D.D.: Detection of glioma-associated gangliosides GM2, GD2, GD3, 3’-isoLM1 3’,6’-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies. Prog. Brain Res. 101, 213–223 (1994). https://doi.org/10.1016/s0079-6123(08)61951-2
doi: 10.1016/s0079-6123(08)61951-2
pubmed: 7518092
Kawai, K., Takahashi, H., Watarai, S., Ishizu, H., Fukai, K., Tanabe, Y., Nose, S., Kuroda, S.: Occurrence of ganglioside GD3 in neoplastic astrocytes. An immunocytochemical study in humans. Virchows Arch. 434, 201–205 (1999). https://doi.org/10.1007/s004280050328
doi: 10.1007/s004280050328
pubmed: 10190298
Vukelić, Z., Kalanj-Bognar, S., Froesch, M., Bîndila, L., Radić, B., Allen, M., Peter-Katalinić, J., Zamfir, A.D.: Human gliosarcoma-associated ganglioside composition is complex and distinctive as evidenced by high-performance mass spectrometric determination and structural characterization. Glycobiology. 17, 504–515 (2007). https://doi.org/10.1093/glycob/cwm012
doi: 10.1093/glycob/cwm012
pubmed: 17293353
Shibuya, H., Hamamura, K., Hotta, H., Matsumoto, Y., Nishida, Y., Hattori, H., Furukawa, K., Ueda, M., Furukawa, K.: Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci. 103, 1656–1664 (2012). https://doi.org/10.1111/j.1349-7006.2012.02344.x
doi: 10.1111/j.1349-7006.2012.02344.x
pubmed: 22632091
pmcid: 7659376
Azuma, K., Tanaka, M., Uekita, T., Inoue, S., Yokota, J., Ouchi, Y., Sakai, R.: Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene. 24, 4754–4764 (2005). https://doi.org/10.1038/sj.onc.1208654
doi: 10.1038/sj.onc.1208654
pubmed: 15870699
Cheresh, D.A., Rosenberg, J., Mujoo, K., Hirschowitz, L., Reisfeld, R.A.: Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res. 46, 5112–5118 (1986)
pubmed: 3019521
Yoshida, S., Fukumoto, S., Kawaguchi, H., Sato, S., Ueda, R., Furukawa, K.: Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 61, 4244–4252 (2001)
pubmed: 11358851
Siddiqui, B., Buehler, J., DeGregorio, M.W., Macher, B.A.: Differential expression of ganglioside GD3 by human leukocytes and leukemia cells. Cancer Res. 44, 5262–5265 (1984)
pubmed: 6488184
Merritt, W.D., Casper, J.T., Lauer, S.J., Reaman, G.H.: Expression of GD3 ganglioside in childhood T-cell lymphoblastic malignancies. Cancer Res. 47, 1724–1730 (1987)
pubmed: 3493067
Furukawa, K., Akagi, T., Nagata, Y., Yamada, Y., Shimotohno, K., Cheung, N.K., Shiku, H., Furukawa, K.: GD2 ganglioside on human T-lymphotropic virus type I-infected T cells: possible activation of beta-1,4-N-acetylgalactosaminyltransferase gene by p40tax. Proc. Natl. Acad. Sci. U.S.A. 90, 1972–1976: (1993). https://doi.org/10.1073/pnas.90.5.1972
Okada, M., Furukawa, K., Yamashiro, S., Yamada, Y., Haraguchi, M., Horibe, K., Kato, K., Tsuji, Y., Furukawa, K.: High expression of ganglioside alpha-2,8-sialyltransferase (GD3 synthase) gene in adult T-cell leukemia cells unrelated to the gene expression of human T-lymphotropic virus type I. Cancer Res. 56, 2844–2848 (1996)
pubmed: 8665524
Cazet, A., Bobowski, M., Rombouts, Y., Lefebvre, J., Steenackers, A., Popa, I., Guérardel, Y., Le Bourhis, X., Tulasne, D., Delannoy, P.: The ganglioside G(D2) induces the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the G(D3) synthase. Glycobiology. 22, 806–816 (2012). https://doi.org/10.1093/glycob/cws049
doi: 10.1093/glycob/cws049
pubmed: 22301273
De Giorgi, U., Cohen, E.N., Gao, H., Mego, M., Lee, B.N., Lodhi, A., Cristofanilli, M., Lucci, A., Reuben, J.M.: Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow. Cancer Biol. Ther. 11, 812–815 (2011). https://doi.org/10.4161/cbt.11.9.15178
doi: 10.4161/cbt.11.9.15178
pubmed: 21358274
pmcid: 3230296
Wiels, J., Fellous, M., Tursz, T.: Monoclonal antibody against a Burkitt lymphoma-associated antigen. Proc. Natl. Acad. Sci. U.S.A. 78, 6485–6488: (1981). https://doi.org/10.1073/pnas.78.10.6485
Nagata, Y., Yamashiro, S., Yodoi, J., Lloyd, K.O., Shiku, H., Furukawa, K.: Expression cloning of beta 1,4 N-acetylgalactosaminyltransferase cDNAs that determine the expression of GM2 and GD2 gangliosides. J. Biol. Chem. 267, 12082–12089 (1992)
doi: 10.1016/S0021-9258(19)49809-8
Haraguchi, M., Yamashiro, S., Yamamoto, A., Furukawa, K., Takamiya, K., Lloyd, K.O., Shiku, H., Furukawa, K.: Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc. Natl. Acad. Sci. U S A. 91, 10455–10459 (1994). https://doi.org/10.1073/pnas.91.22.10455
doi: 10.1073/pnas.91.22.10455
pubmed: 7937974
pmcid: 45039
Nara, K., Watanabe, Y., Maruyama, K., Kasahara, K., Nagai, Y., Sanai, Y.: Expression cloning of a CMP-NeuAc:NeuAc alpha 2-3Gal beta 1-4Glc beta 1–1’Cer alpha 2,8-sialyltransferase (GD3 synthase) from human melanoma cells. Proc. Natl. Acad. Sci. U.S.A. 91, 7952–7956: (1994). https://doi.org/10.1073/pnas.91.17.7952
Sasaki, K., Kurata, K., Kojima, N., Kurosawa, N., Ohta, S., Hanai, N., Tsuji, S., Nishi, T.: Expression cloning of a GM3-specific alpha-2,8-sialyltransferase (GD3synthase). J. Biol. Chem. 269, 15950–15956 (1994)
doi: 10.1016/S0021-9258(17)40773-3
Miyazaki, H., Fukumoto, S., Okada, M., Hasegawa, T., Furukawa, K.: Expression cloning of rat cDNA encoding UDP-galactose:GD2 beta1,3-galactosyl-transferase that determines the expression of GD1b/GM1/GA1. J. Biol. Chem. 272, 24794–24799 (1997). https://doi.org/10.1074/jbc.272.40.24794
doi: 10.1074/jbc.272.40.24794
pubmed: 9312075
Furukawa, K., Tokuda, N., Okuda, T., Tajima, O., Furukawa, K.: Glycosphingolipids in engineered mice: insights into function. Semin Cell. Dev. Biol. 15, 389–396 (2004). https://doi.org/10.1016/j.semcdb.2004.03.006
doi: 10.1016/j.semcdb.2004.03.006
pubmed: 15207829
Stanley, P.: What Have We Learned from Glycosyltransferase Knockouts in Mice? J. Mol. Biol. 428, 3166–3182 (2016). https://doi.org/10.1016/j.jmb.2016.03.025
doi: 10.1016/j.jmb.2016.03.025
pubmed: 27040397
pmcid: 5532804
Yamakawa, T., Iida, T.: Globotetraosylceramide (Gb4) Immuno-chemical study on the red blood cells. I. Globoside, as the agglutinogen of the ABO system on erythrocytes. Jpn J. Exp. Med. 23, 327–331 (1953)
pubmed: 13162652
Yamakawa, T., Yokoyama, S., Handa, N.: Chemistry of lipids of posthemolytic residue or stroma of erythrocytes. XI. Structure of globoside, the main mucolipid of human erythrocytes. J. Biochem. 53, 28–36 (1963). https://doi.org/10.1093/oxfordjournals.jbchem.a127654
doi: 10.1093/oxfordjournals.jbchem.a127654
pubmed: 14002301
Furukawa, K., Iwamura, K., Uchikawa, M., Sojka, B.N., Wiels, J., Okajima, T., Urano, T., Furukawa, K.: Molecular basis for the p phenotype. Identification of distinct and multiple mutations in the alpha 1,4-galactosyltransferase gene in Swedish and Japanese individuals. J. Biol. Chem. 275, 37752–37756 (2000). https://doi.org/10.1074/jbc.C000625200
doi: 10.1074/jbc.C000625200
pubmed: 10993874
Iwamura, K., Furukawa, K., Uchikawa, M., Sojka, B.N., Kojima, Y., Wiels, J., Shiku, H., Urano, T., Furukawa, K.: The blood group P1 synthase gene is identical to the Gb3/CD77 synthase gene. A clue to the solution of the P1/P2/p puzzle. J. Biol. Chem. 278, 44429–44438 (2003). https://doi.org/10.1074/jbc.M301609200
doi: 10.1074/jbc.M301609200
pubmed: 12888565
Kannagi, R., Cochran, N.A., Ishigami, F., Hakomori, S., Andrews, P.W., Knowles, B.B., Solter, D.: Stage-specific embryonic antigens (SSEA-3 and – 4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. EMBO J. 2, 2355–2361 (1983)
doi: 10.1002/j.1460-2075.1983.tb01746.x
Wakao, S., Kushida, Y., Dezawa, M.: Basic Characteristics of Muse Cells. Adv. Exp. Med. Biol. 1103, 13–41 (2018). https://doi.org/10.1007/978-4-431-56847-6_2
doi: 10.1007/978-4-431-56847-6_2
pubmed: 30484222
Mangeney, M., Richard, Y., Coulaud, D., Tursz, T., Wiels, J.: CD77: an antigen of germinal center B cells entering apoptosis. Eur. J. Immunol. 21, 1131–1140 (1991). doi: https://doi.org/10.1002/eji.1830210507
doi: 10.1002/eji.1830210507
pubmed: 1709864
Kovbasnjuk, O., Mourtazina, R., Baibakov, B., Wang, T., Elowsky, C., Choti, M.A., Kane, A., Donowitz, M.: The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc. Natl. Acad. Sci. U. S. A. 102, 19087–19092: (2005) doi: https://doi.org/10.1073/pnas.0506474102
Stimmer, L., Dehay, S., Nemati, F., Massonnet, G., Richon, S., Decaudin, D., Klijanienko, J., Johannes, L.: Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds. BMC Cancer. 14, 916 (2014). doi: https://doi.org/10.1186/1471-2407-14-916
doi: 10.1186/1471-2407-14-916
pubmed: 25476116
pmcid: 4289340
Geyer, P.E., Maak, M., Nitsche, U., Perl, M., Novotny, A., Slotta-Huspenina, J., Dransart, E., Holtorf, A., Johannes, L., Janssen, K.P.: Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit. Mol. Cancer Ther. 15, 1008–10017 (2016). doi: https://doi.org/10.1158/1535-7163.MCT-15-0633
doi: 10.1158/1535-7163.MCT-15-0633
pubmed: 26826119
Senda, M., Ito, A., Tsuchida, A., Hagiwara, T., Kaneda, T., Nakamura, Y., Kasama, K., Kiso, M., Yoshikawa, K., Katagiri, Y., Ono, Y., Ogiso, M., Urano, T., Furukawa, K., Oshima, S., Furukawa, K.: Identification and expression of a sialyltransferase responsible for the synthesis of disialylgalactosylgloboside in normal and malignant kidney cells: downregulation of ST6GalNAc VI in renal cancers. Biochem. J. 402, 459–470 (2007). doi: https://doi.org/10.1042/BJ20061118
doi: 10.1042/BJ20061118
pubmed: 17123352
pmcid: 1863573
Chang, W.W., Lee, C.H., Lee, P., Lin, J., Hsu, C.W., Hung, J.T., Lin, J.J., Yu, J.C., Shao, L.E., Yu, J., Wong, C.H., Yu, A.L.: Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis. Proc. Natl. Acad. Sci. U S A. 105, 11667–11672 (2008). doi: https://doi.org/10.1073/pnas.0804979105
doi: 10.1073/pnas.0804979105
pubmed: 18685093
pmcid: 2575305
Kojima, Y., Fukumoto, S., Furukawa, K., Okajima, T., Wiels, J., Yokoyama, K., Suzuki, Y., Urano, T., Ohta, M., Furukawa, K.: Molecular cloning of globotriaosylceramide/CD77 synthase, a glycosyltransferase that initiates the synthesis of globo series glyco-sphingolipids. J. Biol. Chem. 275, 15152–15156 (2000). https://doi.org/10.1074/jbc.M909620199
doi: 10.1074/jbc.M909620199
pubmed: 10748143
Furukawa, K., Yokoyama, K., Sato, T., Wiels, J., Hirayama, Y., Ohta, M., Furukawa, K.: Gb3 and its derivatives in cultured cells Expression of the Gb3/CD77 synthase gene in megakaryoblastic leukemia cells: implication in the sensitivity to verotoxins. J. Biol. Chem. 277, 11247–11254 (2002). https://doi.org/10.1074/jbc.M109519200
doi: 10.1074/jbc.M109519200
pubmed: 11782470
Okuda, T., Tokuda, N., Numata, S., Ito, M., Ohta, M., Kawamura, K., Wiels, J., Urano, T., Tajima, O., Furukawa, K., Furukawa, K.: Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J. Biol. Chem. 281(15), 10230–10235 (2006). https://doi.org/10.1074/jbc.M600057200
doi: 10.1074/jbc.M600057200
pubmed: 16476743
Kondo, Y., Ikeda, K., Tokuda, N., Nishitani, C., Ohto, U., Akashi-Takamura, S., Ito, Y., Uchikawa, M., Kuroki, Y., Taguchi, R., Miyake, K., Zhang, Q., Furukawa, K., Furukawa, K.: TLR4-MD-2 complex is negatively regulated by an endogenous ligand, globotetraosyl-ceramide. Proc. Natl. Acad. Sci. U.S.A. 110, 4714–4719: (2013). https://doi.org/10.1073/pnas.1218508110
Furukawa, K., Ohkawa, Y., Yamauchi, Y., Hamamura, K., Ohmi, Y., Furukawa, K.: Fine tuning of cell signals by glycosylation. J. Biochem. 151, 573–578 (2012). https://doi.org/10.1093/jb/mvs043
doi: 10.1093/jb/mvs043
pubmed: 22621974
Furukawa, K., Hamamura, K., Ohkawa, Y., Ohmi, Y., Furukawa, K.: Disialyl ganglio-sides enhance tumor phenotypes with differential modalities. Glycoconj. J. 29, 579–584 (2012). https://doi.org/10.1007/s10719-012-9423-0
doi: 10.1007/s10719-012-9423-0
pubmed: 22763744
Hakomori, S.: Cancer-associated glycosphingolipid antigens: their structure, organiza-tion, and function. Acta Anat. (Basel). 161(1–4), 79–90 (1998). https://doi.org/10.1159/000046451
doi: 10.1159/000046451
Hakomori, S., Yamamura, S., Handa, A.K.: Signal transduction through glyco(sphingo-lipids. Introduction and recent studies on glyco(sphingo)lipid-enriched micro-domains. Ann. NY Acad. Sci. 845, 1–10 (1998). https://doi.org/10.1111/j.1749-6632.1998.tb09657.x
doi: 10.1111/j.1749-6632.1998.tb09657.x
pubmed: 9668338
Hakomori, S.: Structure, organization, and function of glyco-sphingolipids in membrane. Curr. Opin. Hematol. 10, 16–24 (2003). https://doi.org/10.1097/00062752-200301000-00004
doi: 10.1097/00062752-200301000-00004
pubmed: 12483107
Hamamura, K., Furukawa, K., Hayashi, T., Hattori, T., Nakano, J., Nakashima, H., Okuda, T., Mizutani, H., Hattori, H., Ueda, M., Urano, T., Lloyd, K.O., Furukawa, K.: Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc. Natl. Acad. Sci. U.S.A. 102, 11041–11046: (2005). https://doi.org/10.1073/pnas.0503658102
Hamamura, K., Tsuji, M., Ohkawa, Y., Nakashima, H., Miyazaki, S., Urano, T., Yamamoto, N., Ueda, M., Furukawa, K., Furukawa, K.: Focal adhesion kinase as well as p130Cas and paxillin is crucially involved in the enhanced malignant properties under expression of ganglioside GD3 in melanoma cells. Biochim. Biophys. Acta. 1780(3), 513–519 (2008). https://doi.org/10.1016/j.bbagen.2007.11.002
doi: 10.1016/j.bbagen.2007.11.002
pubmed: 18078823
Ohkawa, Y., Miyazaki, S., Hamamura, K., Kambe, M., Miyata, M., Tajima, O., Ohmi, Y., Yamauchi, Y., Furukawa, K., Furukawa, K.: Ganglioside GD3 enhances adhesion signals and augments malignant properties of melanoma cells by recruiting integrins to glycolipid-enriched microdomains. J. Biol. Chem. 285, 27213–27223 (2010). https://doi.org/10.1074/jbc.M109.087791
doi: 10.1074/jbc.M109.087791
pubmed: 20581115
pmcid: 2930720
Aixinjueluo, W., Furukawa, K., Zhang, Q., Hamamura, K., Tokuda, N., Yoshida, S., Ueda, R., Furukawa, K.: Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J. Biol. Chem. 280, 29828–29836 (2005). https://doi.org/10.1074/jbc.M414041200
doi: 10.1074/jbc.M414041200
pubmed: 15923178
Nishio, M., Fukumoto, S., Furukawa, K., Ichimura, A., Miyazaki, H., Kusunoki, S., Urano, T., Furukawa, K.: Overexpressed GM1 suppresses nerve growth factor (NGF) signals by modulating the intracellular localization of NGF receptors and membrane fluidity in PC12 cells. J. Biol. Chem. 279, 33368–33378 (2004). https://doi.org/10.1074/jbc.M403816200
doi: 10.1074/jbc.M403816200
pubmed: 15145933
Fukumoto, S., Mutoh, T., Hasegawa, T., Miyazaki, H., Okada, M., Goto, G., Furukawa, K., Urano, T.: GD3 synthase gene expression in PC12 cells results in the continuous activation of TrkA and ERK1/2 and enhanced proliferation. J. Biol. Chem. 275, 5832–5838 (2000). https://doi.org/10.1074/jbc.275.8.5832
doi: 10.1074/jbc.275.8.5832
pubmed: 10681573
Mitsuda, T., Furukawa, K., Fukumoto, S., Miyazaki, H., Urano, T., Furukawa, K.: Overexpression of ganglioside GM1 results in the dispersion of platelet-derived growth factor receptor from glycolipid-enriched microdomains and in the suppression of cell growth signals. J. Biol. Chem. 277, 11239–11246 (2002). https://doi.org/10.1074/jbc.M107756200
doi: 10.1074/jbc.M107756200
pubmed: 11782461
Chen, H.H., Fukumoto, S., Furukawa, K., Nakao, A., Akiyama, S., Urano, T., Furukawa, K.: Suppression of lung metastasis of mouse Lewis lung cancer P29 with transfection of the ganglioside GM2/GD2 synthase gene. Int. J. Cancer. 103, 169–176 (2003). https://doi.org/10.1002/ijc.10797
doi: 10.1002/ijc.10797
pubmed: 12455030
Zhang, Q., Furukawa, K., Chen, H.H., Sakakibara, T., Urano, T., Furukawa, K.: Metastatic potential of mouse Lewis lung cancer cells is regulated via ganglioside GM1 by modulating the matrix metalloprotease-9 localization in lipid rafts. J. Biol. Chem. 28, 18145–18155 (2006). https://doi.org/10.1074/jbc.M512566200)
doi: 10.1074/jbc.M512566200)
Hyuga, S., Yamagata, S., Takatsu, Y., Hyuga, M., Nakanishi, H., Furukawa, K., Yamagata, T.: Suppression by ganglioside GD1A of migration capability, adhesion to vitronectin and metastatic potential of highly metastatic FBJ-LL cells. Int. J. Cancer. 83, 685–691 (1999). doi: https://doi.org/10.1002/(sici)1097-0215(19991126)83:5%3C685::aid-ijc20%3E3.0.co;2-4
doi: 10.1002/(sici)1097-0215(19991126)83:5<685::aid-ijc20>3.0.co;2-4
pubmed: 10521808
Tsurifune, T., Ito, T., Li, X.J., Yamashiro, S., Okada, M., Kanematsu, T., Shiku, H., Furukawa, K.: Alteration of tumor phenotypes of B16 melanoma after genetic remodeling of the ganglioside profile. Int. J. Oncol. 17, 159–165 (2000)
pubmed: 10853034
Dong, Y., Ikeda, K., Hamamura, K., Zhang, Q., Kondo, Y., Matsumoto, Y., Ohmi, Y., Yamauchi, Y., Furukawa, K., Taguchi, R., Furukawa, K.: GM1/GD1b/GA1 synthase expression results in the reduced cancer phenotypes with modulation of composition and raft-localization of gangliosides in a melanoma cell line. Cancer Sci. 101, 2039–2047 (2010). https://doi.org/10.1111/j.1349-7006.2010.01613.x
doi: 10.1111/j.1349-7006.2010.01613.x
pubmed: 20594196
Ono, M., Handa, K., Sonnino, S., Withers, D.A., Nagai, H., Hakomori, S.: GM3 ganglioside inhibits CD9-facilitated haptotactic cell motility: coexpression of GM3 and CD9 is essential in the downregulation of tumor cell motility and malignancy. Biochemistry. 40, 6414–6421 (2001). doi: https://doi.org/10.1021/bi0101998
doi: 10.1021/bi0101998
pubmed: 11371204
Hamamura, K., Tsuji, M., Hotta, H., Ohkawa, Y., Takahashi, M., Shibuya, H., Nakashima, H., Yamauchi, Y., Hashimoto, N., Hattori, H., Ueda, M., Furukawa, K., Furukawa, K.: Functional activation of Src family kinase yes protein is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3. J. Biol. Chem. 286, 18526–18537 (2011). https://doi.org/10.1074/jbc.M110.164798
doi: 10.1074/jbc.M110.164798
pubmed: 21454696
pmcid: 3099669
Ohmi, Y., Kambe, M., Ohkawa, Y., Hamamura, K., Tajima, O., Takeuchi, R., Furukawa, K., Furukawa, K.: Differential roles of gangliosides in malignant properties of melanomas. PLoS One. 13, e0206881 (2018). https://doi.org/10.1371/journal.pone.0206881
doi: 10.1371/journal.pone.0206881
pubmed: 30462668
pmcid: 6248923
Ohkawa, Y., Zhang, P., Momota, H., Kato, A., Hashimoto, N., Ohmi, Y., Bhuiyan, R.H., Farhana, Y., Natsume, A., Wakabayashi, T., Furukawa, K., Furukawa, K.: Lack of GD3 synthase (St8sia1) attenuates malignant properties of gliomas in genetically engineered mouse model. Cancer Sci. 112, 3756–3768 (2021). https://doi.org/10.1111/cas.15032
doi: 10.1111/cas.15032
pubmed: 34145699
pmcid: 8409297
Zhang, P., Ohkawa, Y., Yamamoto, S., Momota, H., Kato, A., Kaneko, K., Natsume, A., Yesmin, F., Ohmi, Y., Okajima, T., Wakabayashi, T., Furukawa, K., Furukawa, K.: St8sia1-deficiency in mice alters tumor environments of gliomas, leading to reduced disease severity. Nagoya J. Med. Sci. 83, 535–549 (2021). https://doi.org/10.18999/nagjms.83.3.535
doi: 10.18999/nagjms.83.3.535
pubmed: 34552288
pmcid: 8438004
Groux-Degroote, S., Guérardel, Y., Delannoy, P.: Gangliosides: Structures, Biosynthesis, Analysis, and Roles in Cancer. Chembiochem. 18, 1146–1154 (2017). https://doi.org/10.1002/cbic.201600705
doi: 10.1002/cbic.201600705
pubmed: 28295942
Simons, K., Ikonen, E.: Functional rafts in cell membranes. Nature. 387, 569–572 (1997). https://doi.org/10.1038/42408
doi: 10.1038/42408
pubmed: 9177342
Hakomori, S.I.: Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility. FEBS Lett. 584, 1901–1906 (2010). https://doi.org/10.1016/j.febslet.2009.10.065
doi: 10.1016/j.febslet.2009.10.065
pubmed: 19874824
Simons, K., Toomre, D.: Lipid rafts and signal transduction. Nat. Rev. Mol. Cell. Biol. 1, 31–39 (2000). https://doi.org/10.1038/35036052
doi: 10.1038/35036052
pubmed: 11413487
Hakomori, S.I., Handa, K.: GM3 and cancer. Glycoconj. J. 32, 1–8 (2015). https://doi.org/10.1007/s10719-014-9572-4
doi: 10.1007/s10719-014-9572-4
pubmed: 25613425
Simons, K., Gerl, M.J.: Revitalizing membrane rafts: new tools and insights. Nat. Rev. Mol. Cell. Biol. 11, 688–699 (2010). https://doi.org/10.1038/nrm2977
doi: 10.1038/nrm2977
pubmed: 20861879
Komura, N., Suzuki, K.G., Ando, H., Konishi, M., Koikeda, M., Imamura, A., Chadda, R., Fujiwara, T.K., Tsuboi, H., Sheng, R., Cho, W., Furukawa, K., Furukawa, K., Yamauchi, Y., Ishida, H., Kusumi, A., Kiso, M.: Raft-based interactions of gangliosides with a GPI-anchored receptor. Nat. Chem. Biol. 12, 402–410 (2016). https://doi.org/10.1038/nchembio.2059
doi: 10.1038/nchembio.2059
pubmed: 27043189
Yesmin, F., Bhuiyan, R.H., Ohmi, Y., Yamamoto, S., Kaneko, K., Ohkawa, Y., Zhang, P., Hamamura, K., Cheung, N.-K.V., Kotani, N., Honke, K., Okajima, T., Kambe, M., Tajima, O., Furukawa, K., Furukawa, K.: Ganglioside GD2 enhances malignant phenotypes of melanoma cells by co-operating with integrins. Int. J. Mol. Sci. 23, 423 (2021). https://doi.org/10.3390/ijms23010423
Furukawa, K., Ohmi, Y., Kondo, Y., Ohkawa, Y., Hashimoto, N., Tajima, O., Furukawa, K.: The role of glycosphingolipifds. Lessons from knockout mice. In: Sillence, D. (ed.) Lipid Rafts. Properties, controversies and roles in signal transduction, pp. 1–20. Nova Publishers, New York (2014)
Sonnino, S., Prinetti, A.: Gangliosides as regulators of cell membrane organization and functions. Adv. Exp. Med. Biol. 688, 165–184 (2010). doi: https://doi.org/10.1007/978-1-4419-6741-1_12
doi: 10.1007/978-1-4419-6741-1_12
pubmed: 20919654
Kotani, N., Gu, J., Isaji, T., Udaka, K., Taniguchi, N., Honke, K.: Biochemical visualization of cell surface molecular clustering in living cells. Proc. Natl. Acad. Sci. U.S.A. 105, 7405–7409: (2008). https://doi.org/10.1073/pnas.0710346105
Hashimoto, N., Hamamura, K., Kotani, N., Furukawa, K., Kaneko, K., Honke, K., Furukawa, K.: Proteomic analysis of ganglioside-associated membrane molecules: substantial basis for molecular clustering. Proteomics. 12, 3154–3163 (2012). https://doi.org/10.1002/pmic.201200279
doi: 10.1002/pmic.201200279
pubmed: 22936677
Kaneko, K., Ohkawa, Y., Hashimoto, N., Ohmi, Y., Kotani, N., Honke, K., Ogawa, M., Okajima, T., Furukawa, K., Furukawa, K.: Neogenin, Defined as a GD3-associated Molecule by Enzyme-mediated Activation of Radical Sources, Confers Malignant Properties via Intracytoplasmic Domain in Melanoma Cells. J. Biol. Chem. 291, 16630–16643 (2016). https://doi.org/10.1074/jbc.M115.708834
doi: 10.1074/jbc.M115.708834
pubmed: 27288875
pmcid: 4974378
Ohkawa, Y., Momota, H., Kato, A., Hashimoto, N., Tsuda, Y., Kotani, N., Honke, K., Suzumura, A., Furukawa, K., Ohmi, Y., Natsume, A., Wakabayashi, T., Furukawa, K.: Ganglioside GD3 Enhances Invasiveness of Gliomas by Forming a Complex with Platelet-derived Growth Factor Receptor α and Yes Kinase. J. Biol. Chem. 290, 16043–16058 (2015). https://doi.org/10.1074/jbc.M114.635755
doi: 10.1074/jbc.M114.635755
pubmed: 25940087
pmcid: 4481208
Esaki, N., Ohkawa, Y., Hashimoto, N., Tsuda, Y., Ohmi, Y., Bhuiyan, R.H., Kotani, N., Honke, K., Enomoto, A., Takahashi, M., Furukawa, K., Furukawa, K.: ASC amino acid transporter 2, defined by enzyme-mediated activation of radical sources, enhances malignancy of GD2-positive small-cell lung cancer. Cancer Sci. 109, 141–153 (2018)
doi: 10.1111/cas.13448
Irie, R.F., Ollila, D.W., O’Day, S., Morton, D.L.: Phase I pilot clinical trial of human IgM monoclonal antibody to gangliosideGM3 in patients with metastatic melanoma. Cancer Immunol. Immunother. 53, 110–117 (2004). https://doi.org/10.1007/s00262-003-0436-1
doi: 10.1007/s00262-003-0436-1
pubmed: 14564483
Becker, J.C., Varki, N., Gillies, S.D., Furukawa, K., Reisfeld, R.A.: An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. U S A. 93, 7826–7831 (1996). doi: https://doi.org/10.1073/pnas.93.15.7826
doi: 10.1073/pnas.93.15.7826
pubmed: 8755561
pmcid: 38833
Kushner, B.H., Ostrovnaya, I., Cheung, I.Y., Kuk, D., Kramer, K., Modak, S., Yataghene, K., Cheung, N.K.: Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G(D2) immunotherapy and isotretinoin: a prospective Phase II study. Oncoimmunology. 4, e1016704 (2015). https://doi.org/10.1080/2162402X.2015.1016704
doi: 10.1080/2162402X.2015.1016704
pubmed: 26140243
pmcid: 4485744
Yu, J., Hung, J.T., Wang, S.H., Cheng, J.Y., Yu, A.L.: Targeting glyco-sphingolipids for cancer immunotherapy. FEBS Lett. 594, 3602–3618 (2020). doi: https://doi.org/10.1002/1873-3468.13917
doi: 10.1002/1873-3468.13917
pubmed: 32860713
Harel, W., Shau, H., Hadley, C.G., Morgan, A.C. Jr., Reisfeld, R.,A., Cheresh, D.A., Mitchell, M.S.: Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Cancer Res. 50, 6311–6315 (1990)
pubmed: 2400994
McLaughlin, P., Grillo-López, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D., Dallaire, B.K.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825–2833 (1998)
doi: 10.1200/JCO.1998.16.8.2825
Furukawa, K., Hamamura, K., Aixinjueluo, W., Furukawa, K.: Biosignals modulated by tumor-associated carbohydrate antigens: novel targets for cancer therapy. Ann. NY Acad. Sci. 1086, 185–198 (2006). https://doi.org/10.1196/annals.1377.017
doi: 10.1196/annals.1377.017
pubmed: 17185516
Ko, K., Furukawa, K., Takahashi, T., Urano, T., Sanai, Y., Nagino, M., Nimura, Y., Furukawa, K.: Fundamental study of small interfering RNAs for ganglioside GD3 synthase gene as a therapeutic target of lung cancers. Oncogene. 25, 6924–6935 (2006). https://doi.org/10.1038/sj.onc.1209683
doi: 10.1038/sj.onc.1209683
pubmed: 16862187
Makino, Y., Hamamura, K., Takei, Y., Buiyan, R.H., Ohkawa, Y., Ohmi, Y., Nakashima, H., Furukawa, K., Furukawa, K.: A therapeutic trial of human melanomas with combined small interfering RNAs targeting adaptor molecules p130Cas and paxillin activated under expression of ganglioside GD3. Biochim. Biophys. Acta. 1860, 1753–1763 (2016). https://doi.org/10.1016/j.bbagen.2016.04.005
doi: 10.1016/j.bbagen.2016.04.005
pubmed: 27068854
Furukawa, K., Hamamura, K., Nakashima, H., Furukawa, K.: Molecules in the signaling pathway activated by gangliosides can be targets of therapeutics for malignant melanomas. Proteomics. 8, 3312–3316 (2008). https://doi.org/10.1002/pmic.200800228
doi: 10.1002/pmic.200800228
pubmed: 18690647
Furukawa, K., Ohmi, Y., Ohkawa, Y., Bhuiyan, R.H., Zhang, P., Tajima, O., Hashimoto, N., Hamamura, K., Furukawa, K.: New era of research on cancer-associated glycosphingolipids. Cancer Sci. 110, 1544–1551 (2019). https://doi.org/10.1111/cas.14005
doi: 10.1111/cas.14005
pubmed: 30895683
pmcid: 6501054
Brignole, C., Pagnan, G., Marimpietri, D., Cosimo, E., Allen, T.M., Ponzoni, M., Pastorino, F.: Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer Lett. 197, 231–235 (2003). doi: https://doi.org/10.1016/s0304-3835(03)00107-1
doi: 10.1016/s0304-3835(03)00107-1
pubmed: 12880987
Prigione, I., Corrias, M.V., Airoldi, I., Raffaghello, L., Morandi, F., Bocca, P., Cocco, C., Ferrone, S., Pistoia, V.: Immunogenicity of human neuroblastoma. Ann. N Y Acad. Sci. 1028, 69–80 (2004). doi: https://doi.org/10.1196/annals.1322.008
doi: 10.1196/annals.1322.008
pubmed: 15650233
Mount, C.W., Majzner, R.G., Sundaresh, S., Arnold, E.P., Kadapakkam, M., Haile, S., Labanieh, L., Hulleman, E., Woo, P.J., Rietberg, S.P., Vogel, H., Monje, M., Mackall, C.L.: Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
doi: 10.1038/s41591-018-0006-x
pubmed: 29662203
pmcid: 6214371